Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $99.06, for a total value of $495,300.00. Following the transaction, the chief executive officer now directly owns 33,961 shares in the company, valued at approximately $3,364,176.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ BPMC traded down $1.03 during mid-day trading on Wednesday, hitting $96.77. The company had a trading volume of 689,723 shares, compared to its average volume of 466,875. The company has a market cap of $4.73 billion, a price-to-earnings ratio of -17.95 and a beta of 1.45. Blueprint Medicines Corp has a 12 month low of $44.58 and a 12 month high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.15). The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.38 million. Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The company’s revenue for the quarter was down 23.2% on a year-over-year basis. During the same period last year, the business posted ($1.29) EPS. As a group, equities analysts forecast that Blueprint Medicines Corp will post -7.76 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in BPMC. Hillhouse Capital Advisors Ltd. bought a new stake in Blueprint Medicines during the 4th quarter valued at $77,142,000. Norges Bank bought a new stake in Blueprint Medicines during the 4th quarter valued at $42,705,000. FMR LLC raised its stake in Blueprint Medicines by 5.3% during the 1st quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock valued at $555,491,000 after acquiring an additional 346,738 shares in the last quarter. Foresite Capital Management III LLC raised its stake in Blueprint Medicines by 133.8% during the 4th quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock valued at $25,213,000 after acquiring an additional 267,682 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in Blueprint Medicines during the 1st quarter valued at $21,105,000. 97.46% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Jeffrey W. Albers Sells 5,000 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4379902/jeffrey-w-albers-sells-5000-shares-of-blueprint-medicines-corp-nasdaqbpmc-stock.html.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.